Cannabis
Mycrodose Therapeutics to Discuss Advanced Drug Delivery Devices at Psychedelic Medicine Event
San Diego, California–(Newsfile Corp. – July 27, 2021) – Mycrodose Therapeutics, a US-Based pharmaceutical company focused on developing advanced drug delivery systems for use with psychedelic compounds, announced today that its Executive team will be participating in the upcoming Psychedelic Capital Event on July 29, 2021.
The virtual conference hosted by Microdose Psychedelic Insights will enable Mycrodose Therapeutics the opportunity to present as a panel on the company’s core drug delivery systems, their major milestones & accomplishments, and the company’s outlook on the expanding psychedelic pharmaceutical sector.
“Mycrodose Therapeutics started from a deep personal need to find better solutions for treating mental health. We have a deep desire of improving the fight against the mental health pandemic that impacts all ages, all ethnicities, all genders, and spans the entire globe. Our continued mission is to develop cutting-edge technologies and novel IP in order to bring more happiness, love, connection, and understanding to those suffering. We look forward to sharing more at the Psychedelic Capital Event this week.” – Patrick Eckstrom, Chief Operating Officer.
Panel Topic: Advanced Drug Delivery of Psychedelic Compounds
Panel Presenters: Chad Conner, Chief Executive Officer; Frank Kochinke, Chief Science Officer; Patrick Eckstrom, Chief Operating Officer
Date: Thursday, July 29, 2021
Time: 10:30 AM PST (1:30 PM EST) – Introduction by Patrick Moher, CEO of Microdose Psychedelic Insights, and Richard Skaife, Co-Founder of The Conscious Fund.
10:45 AM PST (1:45 PM EST) – Presentation by Mycrodose Therapeutics
Tickets: FREE Only Through This Link: https://microdose.buzz/discount/psycap/
About Mycrodose Therapeutics
Mycrodose Therapeutics is a US-Based pharmaceutical company headquartered in San Diego, California specializing in the development of advanced drug delivery systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. Mycrodose is one of only a few private companies that has been granted a Schedule I License to research four (4) psychedelic compounds: Psilocybin, MDMA, DMT & LSD by the United States Drug Enforcement Agency (DEA).
For more information about Mycrodose Therapeutics, please contact:
Patrick Eckstrom
Chief Operating Officer
Mycrodose Therapeutics
Email: [email protected]
Phone: 1-619-494-1367
Website: www.MycrodoseThera.com
Cannabis
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Innocan2 weeks ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf2 weeks ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis2 weeks ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis4 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
SCHWAZZE5 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis4 days ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Humboldt4 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
Cannabis2 days ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III